328 related articles for article (PubMed ID: 33117811)
1. Functional Versatility of the CDK Inhibitor p57
Creff J; Besson A
Front Cell Dev Biol; 2020; 8():584590. PubMed ID: 33117811
[TBL] [Abstract][Full Text] [Related]
2. p57KIP2: "Kip"ing the cell under control.
Pateras IS; Apostolopoulou K; Niforou K; Kotsinas A; Gorgoulis VG
Mol Cancer Res; 2009 Dec; 7(12):1902-19. PubMed ID: 19934273
[TBL] [Abstract][Full Text] [Related]
3. p57(Kip2) and cancer: time for a critical appraisal.
Borriello A; Caldarelli I; Bencivenga D; Criscuolo M; Cucciolla V; Tramontano A; Oliva A; Perrotta S; Della Ragione F
Mol Cancer Res; 2011 Oct; 9(10):1269-84. PubMed ID: 21816904
[TBL] [Abstract][Full Text] [Related]
4. p57(Kip2) knock-in mouse reveals CDK-independent contribution in the development of Beckwith-Wiedemann syndrome.
Duquesnes N; Callot C; Jeannot P; Daburon V; Nakayama KI; Manenti S; Davy A; Besson A
J Pathol; 2016 Jul; 239(3):250-61. PubMed ID: 27015986
[TBL] [Abstract][Full Text] [Related]
5. A Beckwith-Wiedemann-Associated
Stampone E; Bencivenga D; Barone C; Di Finizio M; Della Ragione F; Borriello A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299047
[TBL] [Abstract][Full Text] [Related]
6. The cyclin-dependent kinase inhibitor p57Kip2 regulates cell cycle exit, differentiation, and migration of embryonic cerebral cortical precursors.
Tury A; Mairet-Coello G; DiCicco-Bloom E
Cereb Cortex; 2011 Aug; 21(8):1840-56. PubMed ID: 21245411
[TBL] [Abstract][Full Text] [Related]
7. The multiple roles of the cyclin-dependent kinase inhibitory protein p57(KIP2) in cerebral cortical neurogenesis.
Tury A; Mairet-Coello G; DiCicco-Bloom E
Dev Neurobiol; 2012 Jun; 72(6):821-42. PubMed ID: 22076965
[TBL] [Abstract][Full Text] [Related]
8. Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases.
Stampone E; Caldarelli I; Zullo A; Bencivenga D; Mancini FP; Della Ragione F; Borriello A
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614816
[TBL] [Abstract][Full Text] [Related]
9. Increased IGF-II protein affects p57kip2 expression in vivo and in vitro: implications for Beckwith-Wiedemann syndrome.
Grandjean V; Smith J; Schofield PN; Ferguson-Smith AC
Proc Natl Acad Sci U S A; 2000 May; 97(10):5279-84. PubMed ID: 10779549
[TBL] [Abstract][Full Text] [Related]
10. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development.
Yan Y; Frisén J; Lee MH; Massagué J; Barbacid M
Genes Dev; 1997 Apr; 11(8):973-83. PubMed ID: 9136926
[TBL] [Abstract][Full Text] [Related]
11. The developmental expression of the CDK inhibitor p57(kip2) (Cdkn1c) in the early mouse placenta.
Saunders AC; McGonnigal B; Uzun A; Padbury J
Mol Reprod Dev; 2016 May; 83(5):405-12. PubMed ID: 26988311
[TBL] [Abstract][Full Text] [Related]
12. Distant cis-elements regulate imprinted expression of the mouse p57( Kip2) (Cdkn1c) gene: implications for the human disorder, Beckwith--Wiedemann syndrome.
John RM; Ainscough JF; Barton SC; Surani MA
Hum Mol Genet; 2001 Jul; 10(15):1601-9. PubMed ID: 11468278
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.
Pateras IS; Apostolopoulou K; Koutsami M; Evangelou K; Tsantoulis P; Liloglou T; Nikolaidis G; Sigala F; Kittas C; Field JK; Kotsinas A; Gorgoulis VG
Int J Cancer; 2006 Dec; 119(11):2546-56. PubMed ID: 16988944
[TBL] [Abstract][Full Text] [Related]
14. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
Matsuoka S; Edwards MC; Bai C; Parker S; Zhang P; Baldini A; Harper JW; Elledge SJ
Genes Dev; 1995 Mar; 9(6):650-62. PubMed ID: 7729684
[TBL] [Abstract][Full Text] [Related]
15. A pro-apoptotic effect of the CDK inhibitor p57(Kip2) on staurosporine-induced apoptosis in HeLa cells.
Samuelsson MK; Pazirandeh A; Okret S
Biochem Biophys Res Commun; 2002 Aug; 296(3):702-9. PubMed ID: 12176039
[TBL] [Abstract][Full Text] [Related]
16. The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer.
Zohny SF; Baothman OA; El-Shinawi M; Al-Malki AL; Zamzami MA; Choudhry H
Cancer Biomark; 2017; 18(4):413-423. PubMed ID: 28106536
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of p57kip² promotes cell invasion via LIMK/cofilin pathway in human nasopharyngeal carcinoma cells.
Chow SE; Wang JS; Lin MR; Lee CL
J Cell Biochem; 2011 Nov; 112(11):3459-68. PubMed ID: 21769918
[TBL] [Abstract][Full Text] [Related]
18. Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors.
Starostina NG; Kipreos ET
Trends Cell Biol; 2012 Jan; 22(1):33-41. PubMed ID: 22154077
[TBL] [Abstract][Full Text] [Related]
19. Assessment of p57(KIP2) gene mutation in Beckwith-Wiedemann syndrome.
Gaston V; Le Bouc Y; Soupre V; Vazquez MP; Gicquel C
Horm Res; 2000; 54(1):1-5. PubMed ID: 11182628
[TBL] [Abstract][Full Text] [Related]
20. CDK inhibitors, p21(Cip1) and p27(Kip1), participate in cell cycle exit of mammalian cardiomyocytes.
Tane S; Ikenishi A; Okayama H; Iwamoto N; Nakayama KI; Takeuchi T
Biochem Biophys Res Commun; 2014 Jan; 443(3):1105-9. PubMed ID: 24380855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
